Advanced Hip Osteoarthritis and Kidney Disease: Pain Control Before a Delayed Surgery
NSAIDs are essentially closed off by his kidney disease and a prior GI bleed, and his hip replacement is on hold until cardiology clears him. The group disagrees about what should fill that gap.
Walter G., 72, has lived with his wife of forty-five years in the same split-level house since their children were small, and spends most weekday evenings in the basement working on a model railroad layout that now takes up more square footage than either of them planned for. Retirement three years ago gave him more time for it, and it should be the best stretch of that hobby he's had — except he has spent most of the time since noticing how much of ordinary life runs through his right hip — getting out of a car, standing at the stove, and most of all the stairs down to that basement layout, a trip he has started quietly dreading rather than looking forward to. Advanced osteoarthritis has made all of it progressively harder over the past year, and he and his surgeon have already agreed a total hip arthroplasty is the right long-term answer; there's no disagreement left about the destination. What's keeping him from getting there is a recent stress test that turned up borderline ischemia, enough that cardiology wants a fuller workup before he's cleared for an elective procedure — a real delay, not a hypothetical one, and nobody yet knows how long it will take.
In the meantime, his medical options are narrower than they'd be for most patients his age. His kidney function has declined to CKD stage 4, an eGFR of 25, which puts chronic NSAID therapy of any kind at real risk of accelerating that decline further, a tradeoff his nephrologist has already flagged directly. That same number sits below 30 — the creatinine-clearance line at which tramadol's label stops describing an ordinary regimen and starts requiring a longer dosing interval — so his kidneys narrow not only which drugs remain but how they may be given. A GI bleed attributed to NSAID use over a decade ago adds a second, independent reason to avoid that route entirely rather than simply use it cautiously. Acetaminophen alone isn't controlling his pain well enough to get him through the wait, and he has started limiting how often he leaves the house, which is its own quiet cost nobody has explicitly named yet. The 2022 CDC opioid guideline replaced its 2016 predecessor's hard dose ceilings with individualized decisions, and tramadol sits in disputed ground within that framework — closer to a true opioid than its reputation suggests, but with its own evidence base and risk profile. For Walter that shift moves the question off whether he clears a threshold and onto what a defensible course looks like for a man whose fix is scheduled and merely unavailable — a question about duration and interval, not dose ceilings.
Bridging the wait for cardiac clearance
Walter's options are genuinely narrow. NSAIDs are out on two separate grounds — his kidney function and his prior GI bleed — and there's no topical or intra-articular route that reaches a hip the way there is for a knee. Acetaminophen alone isn't getting him through his days.
Tramadol sits in a conditional-recommendation tier the 2019 ACR guideline treats differently from the non-tramadol opioids the same guideline recommends against. Given what's actually left on the table for him, I'd start it now.
One thing that is not optional, though, and is easy to get wrong precisely because his daily total looks acceptable: at an eGFR of 25 he is below the creatinine-clearance threshold of 30 at which the label stops treating this as an ordinary prescription. Tramadol and its active M1 metabolite are both renally cleared, so the labeled adjustment is to stretch the dosing interval to every twelve hours, with 200mg as the absolute daily ceiling. Fifty milligrams four times a day would hit that ceiling while dosing him at a healthy kidney's interval — the total would look fine on the chart and he would still accumulate.
I take the contraindications seriously, but I don't think 'the alternatives are limited' automatically means an opioid-class drug is the right next step. The 2019 Cochrane review of tramadol in osteoarthritis is the honest summary here, and it is harsher than the drug's reputation: moderate-quality evidence that tramadol has no important benefit on mean pain or function against placebo, with only slightly more patients reporting an improvement they'd call meaningful. What it does reliably produce is withdrawal for adverse events — a relative risk of 2.64, about a twelve-percentage-point absolute increase over placebo. That trade reads differently at seventy-two — falls, sedation and dependence potential in exactly the age group he's in.
If we've genuinely run out of medical options for a 72-year-old, that's a signal to push the cardiology timeline, not necessarily to start a chronic-use drug for a problem that already has a scheduled fix.
That's the piece I think resolves this. Walter isn't someone we're managing indefinitely — he has a hip replacement already agreed and scheduled to happen as soon as cardiology clears him. The actual question isn't whether tramadol is right for chronic osteoarthritis pain management in general, it's whether it's reasonable to get one specific patient through one specific, bounded wait.
Start it now, but frame it explicitly as a bridge with a defined endpoint — his surgical date, or a re-evaluation point if the cardiac workup runs long — rather than an open prescription. I'll also push to get the cardiology timeline itself moving faster where I can, so the bridge doesn't have to run longer than it needs to.
Agreed: start tramadol as a bridge therapy explicitly tied to his surgical timeline, with a re-evaluation point set regardless of how the cardiology workup proceeds. The orthopedic surgeon agreed to follow up directly with cardiology on the pace of that workup rather than leaving the timeline entirely open.
Tramadol stops at surgery, and the bridge functioned exactly as intended, without ever becoming a standing regimen.
The group agreed to formally reassess rather than simply continuing tramadol by default, since an open-ended 'bridge' is the outcome all three voices wanted explicitly to avoid.
Not agreed: how long a delay would be long enough to revisit the opioid-avoidance position altogether. The geriatrician's discomfort with tramadol was tied specifically to it being time-limited; if the wait stretches past a few months, that calculus changes in ways the group didn't fully resolve today.